fair assessment.. 15% shares diluted, with the current market caps of $470 Mil, AGEN should be traded around $5.50ish until the major positive news is announcement or BO.. there's no reason to buy in higher than $6. gl
if you signed an exclusive deal and don't get a huge amount of money upfront, then you're giving IPs away.. JnJ payouts were based on the contingency of getting the FDA approval and sale of drugs which will not happen for another 2 years.. IPs transfer process will be completed in a few months...
ACHN investors get fecked big time..
WS is a corrupted institution.. these crooks should be locked up in an institution.. wonder why they call themselves as institutional investors.. simply because they are crooked.
if JnJ spends $225MILLION / 18.4Million shares = $12.25 this week, then it is a good deal for ACHN.
If JnJ only acquired 18.4 Mil shares @$12.25 after the FDA approval, then ACHN management is giving IPs away for nothing.. This deal is NOT good for the current shareholders, this deal is only good for ACHN management because they will loot this cash by giving themselves huge bonuses and stock options for completing this deal with JnJ... gradually, stock price will going lower.. until the FDA approval.. GL
milestone payments are still few years away, including sales & FDA approvals.. but technology transfer will happen within months... no timeline was specified for $225Mil equity investment which means JnJ can delayed until they can maximize their investments.. after the technology transferred, ACHN is finished..
ACHN get no payment upfront before the technology transfer process.. this is NOT smart move by the ACHN leadership team.. similar exclusive deal happened to MNKD and SNY, MNKD stocked dropped more than 60% after the announcement, expecting the same with this deal..
exclusive licencing means, JnJ will drive the value to the ground so they don't have to payout the milestones while acquired the IP to develop other drugs using the ACHN platform for free.. this mgtment team is not watching out for shareholders value.. they were watching out for their own paid out.. feck this #$%$.. another bio-scam..
let me know how many shares do you like to short and I will be selling them to you.. it just jumped to 10.85.. 15 cents more and your wishes will be fulfilled..
you can either short this stock or stop making mindless speculations without logic behind your numbers. you need to grow up..
stock is not moving upward at all.. total manipulation by the MMs.. this kind of event should be a great deal to a small caps company, but nada...
if we get the goods, don't need to over-exposing because it looks cheap and sleezzy.. on the other hand, marginal products need more booths at the ASCO.
as the article stated, The FDA doesn’t have to follow the direction of its advisory panels but it usually does. Apparently documents released Monday suggested the FDA should not consider an accelerated review for T-VEC. And during Wednesday’s meeting, some committee members expressed worries that the late-stage trial didn’t provide compelling evidence that T-VEC improves overall survival. The FDA had already pushed back the decision date from July 28 to October 27, and investors were skeptical: Amgen’s stock dipped 3.6% on Monday to $162.38.
It appears to me that FDA has to lower the bar to approve AMGN's drugs? that mean they have to approve more marginal drugs than they should? or FDA only approved marginal drugs for big pharma companies but CLDX may not benefit from this deviate approval process!
Holy Cow!!!! They over-inflated credentials to get hired, but they don't listen well, set unrealistic expectations and won't fit into American cultures where innovations and mistakes were allowed...
100% agreed with your statement...
$3.59 cash per share + IPs, this stock should be up above $7 within 2 weeks.. there're some other trials on going.. in the meantime, data is being reviewed to see if they need to improve screening process to select the right patients for the next trial.. if FDA allows CLDN to conduct P2B or P3 after data shows great benefits to narrow range of patients, CLDN could rise from the ashes... GL
she's worse than Bernie Maddoff..how can she be surprise when data has been collected and analyzed daily until she decided to release to public .. she made statement such as looking forward to upcoming checkpoint, or made announcement wrt mfg expansion to meet the demand.. generating a bunch of deceive actions while she unloaded her shares.. she probably leaked this data to her hedgies buddies to short on stock as well... so many coincidences that lead to final announcement yesterday..
the whole thing was a scam manipulated by professional scam artist...